Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%
Market cap
$681.6M
P/E
62.4×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 5 6 6 2 3 5
P/E ratio
80.75 80.75 80.75 80.75 77.31 63.00 60.74 0.00 0.00 441.75
Altman Z-Score
— — — — 3.12 1.95 2.34 2.15 2.59 3.88
P/S ratio
52.19 52.19 52.19 52.19 44.99 29.41 3.65 3.08 2.27 3.24
Altman Z″-Score (non-manufacturers)
(7.55) — — (1.44) 2.66 2.33 2.65 2.37 2.26 2.28
P/FCF ratio
57.90 57.90 57.90 57.90 79.97 314.61 50.50 0.00 0.00 22.56
Beneish M-Score
— — — (2.59) (2.98) (2.95) (2.71) (1.94) (2.36) (2.78)
P/Operating CF
164.75 164.75 164.75 164.75 489.96 382.16 138.41 65.27 72.45 113.67
P/B ratio
66.90 66.90 66.90 66.90 52.65 30.09 3.69 3.45 3.06 4.39
Price to Tangible BV
153.70 153.70 153.70 153.70 108.09 53.21 5.83 5.12 4.22 8.60
EV/Sales
52.01 52.01 52.01 52.01 44.79 29.25 3.29 2.77 1.99 3.02
EV/EBITDA
127.13 127.13 127.13 127.13 114.81 188.57 41.83 64.58 79.28 30.63
EV/Operating CF
57.70 57.70 57.70 57.70 74.71 167.87 25.07 (39.33) (329.00) 20.75
EV/FCF
57.70 57.70 57.70 57.70 79.60 312.97 45.55 (34.00) (184.03) 21.04
Quick Ratio
0.84 1.13 1.17 0.90 3.15 4.75 3.94 3.33 3.02 2.03
Current Ratio
1.21 1.45 1.40 1.05 3.43 5.33 4.65 4.06 3.77 2.59
Net Debt/EBITDA
(3.29) 0.96 (0.18) (0.25) (0.64) (1.55) (2.36) (7.12) (11.48) (2.21)
Debt/Assets
53.16% 0.00% 33.99% 21.90% 36.27% 35.46% 31.33% 29.91% 20.60% 19.61%
Debt/Equity
2.45 5.10 1.18 0.48 0.83 0.73 0.65 0.63 0.37 0.35
Asset Turnover
0.10 1.62 0.82 0.75 0.63 0.49 0.50 0.55 0.69 0.84
Operating CF/Net income
0.57 (0.40) 1.17 1.84 2.22 2.37 1.64 1.64 0.15 19.19
Capex/Depreciation
0.00 0.00 0.00 (4.39) (1.84) (0.85) (0.15) (0.09) (0.05) (0.07)
Interest Coverage
(3.80) 0.00 0.00 — — — — — — —
ROE
(76.40%) (380.21%) 63.57% 43.08% 25.11% 8.50% 6.88% (4.98%) (5.38%) 1.14%
ROA
(11.06%) (137.67%) 15.12% 16.14% 11.20% 3.92% 3.32% (2.37%) (2.74%) 0.63%
ROIC
0.00% 0.00% 0.00% 43.09% 36.93% 5.98% 8.73% (2.34%) (3.97%) 8.27%
Return on Tangible Assets
(104.04%) (213.33%) 60.60% 274.83% 19.01% 7.41% 5.99% (4.25%) (5.58%) 1.49%
Average Days of Receivables
261.82 41.47 43.22 55.58 61.76 55.03 49.03 68.68 67.33 53.08
Research and Development Expense of Revenue
92.81% 20.26% 20.71% 16.78% 18.15% 35.38% 25.55% 28.09% 27.98% 26.68%
Selling, General and Administrative Expense of Revenue
47.74% 38.55% 32.50% 34.80% 35.67% 48.48% 64.11% 73.34% 63.75% 56.08%
Intangible Assets out of Total Assets
0.45 0.00 0.24 0.31 0.22 0.21 0.18 0.15 0.15 0.27
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 2.26% 3.08% 4.55% 3.11% 3.77% 3.78% 3.66%
Graham Net Nets
0.00 0.00 0.00 0.00 0.00 0.01 0.07 0.10 0.15 0.06
Graham Number
0.00 0.00 0.00 0.00 1.13 0.97 3.65 0.00 0.00 1.90
Earnings Yield
1.24% 1.24% 1.24% 1.24% 1.29% 1.59% 1.65% (1.74%) (1.79%) 0.23%
Free Cash Flow Yield
1.73% 1.73% 1.73% 1.73% 1.25% 0.32% 1.98% (2.65%) (0.47%) 4.43%
Revenue per Share
0.04 0.22 2.53 3.02 3.33 3.10 3.17 3.73 4.43 5.46
Operating CF per Share
(0.03) 0.07 0.55 1.19 1.31 0.59 0.35 (0.26) (0.03) 0.79
Capex per Share
0.00 0.00 0.00 (0.41) (0.24) (0.26) (0.03) (0.02) (0.01) (0.01)
Free Cash Flow per Share
(0.03) 0.07 0.55 0.78 1.07 0.33 0.32 (0.29) (0.04) 0.78
Cash per Share
0.08 0.14 1.50 1.19 3.24 2.99 3.20 3.25 2.50 2.61
Shareholders Equity per Share
0.07 0.04 1.16 1.87 2.88 3.00 3.15 3.33 3.29 4.02
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.07 0.04 1.16 1.87 2.88 3.00 3.15 3.33 3.29 4.02
Free Cash Flow
(10.53) 36.55 33.69 49.04 68.33 21.13 20.48 (18.77) (2.59) 53.95
Working Capital
11.38 33.14 37.75 5.17 186.36 202.67 217.80 238.37 204.64 183.68
Capital Expenditures
(1.59) (7.28) (4.33) (25.44) (15.30) (16.72) (1.98) (1.46) (0.80) (0.75)
Net Current Asset Value
(39.08) (74.49) (42.96) (19.07) 28.19 45.05 56.34 72.27 99.52 76.61
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 8.77 0.00 0.00 43.93
Capex to Sales
0.00 0.00 0.00 0.13 0.07 0.08 0.01 0.01 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 9.72 0.00 0.00 47.10
Other line items
Depreciation/Fixed assets
0.13 0.41 0.47 0.61 0.68 1.48 1.27 1.64 2.07 1.55
Cash ROIC
(7.89%) 19.32% 13.63% 19.82% 12.62% 4.02% 3.75% (3.29%) (0.55%) 9.72%
Accounts Receivable Turnover
1.38 8.90 10.13 8.02 6.56 6.04 7.14 6.65 5.89 6.87
Accounts Payable Turnover
0.66 2.20 3.14 0.99 0.53 0.47 0.36 0.40 0.51 0.53
Inventory Turnover
0.28 0.93 1.42 1.32 1.26 0.87 0.50 0.51 0.63 0.75
Average Days of Payables
379.29 217.97 93.51 619.53 739.12 733.26 1,131.97 1,050.00 686.83 849.52
Days of Inventory on Hand
1,203.98 423.78 243.78 247.27 328.06 471.49 879.68 821.73 574.57 520.64
Average Receivables
12.13 12.13 15.33 23.61 32.36 32.94 28.80 36.89 50.49 54.76
Average Payables
8.66 8.66 9.50 24.12 44.13 45.07 48.47 63.50 69.57 86.26
Average Inventory
20.49 20.49 21.00 18.05 18.68 24.23 34.82 49.54 56.24 60.31
Average Assets
166.84 66.73 190.04 251.11 337.02 407.88 411.56 444.33 431.42 449.97
Average Common Equity
24.16 24.16 45.19 94.11 150.34 188.18 198.78 211.71 219.92 249.08

Fold the line items

Columns are period end dates